<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678467</url>
  </required_header>
  <id_info>
    <org_study_id>EB-CMF-02</org_study_id>
    <nct_id>NCT03678467</nct_id>
  </id_info>
  <brief_title>Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction</brief_title>
  <acronym>EB-CMF</acronym>
  <official_title>An Open-Label, First-in-Human, Single Intervention Study for Evaluation of EpiBone-CMF Engineered Living Bone Graft for Mandibular Ramus Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epibone, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epibone, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EpiBone-Craniomaxillofacial (EB-CMF) is an autologous, anatomically shaped bone graft created
      specifically for the patient's defect, using the patients own adipose-derived mesenchymal
      stem cells. This first in human trial is designed specifically to assess the safety of EB-CMF
      clinically. Although secondary measures of graft efficacy are being assessed, the primary
      focus will be on Adverse Events stemming from graft implantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety of EB-CMF for up to 12 months post surgery in subjects with recent or remote mandibular ramus defects requiring up to a 15 cc graft reconstruction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone regeneration as assessed by high-resolution CT scans</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the efficacy of the EpiBone-CMF graft for up to 12 months post-surgery in subjects with recent or remote mandibular ramus defects requiring up to a 15 cc graft reconstruction. Bone regeneration as assessed by high-resolution CT scans for up to 12 months post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Glasgow Benefit Inventory</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the changes in quality of life for up to 12 months post-surgery in patients as measured by the Glasgow Benefit Inventory.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Observational assessment of bone regeneration by high-resolution CT scan</measure>
    <time_frame>10 Years</time_frame>
    <description>Yearly observation of bone regeneration by high-resolution CT scan until the subject withdraws from the study or termination of the study.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Mandible Tumor</condition>
  <condition>Mandibular Injuries</condition>
  <condition>Mandible; Deformity</condition>
  <arm_group>
    <arm_group_label>EB-CMF Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject receiving EB-CMF implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EB-CMF</intervention_name>
    <description>Autologous, anatomically shaped bone graft</description>
    <arm_group_label>EB-CMF Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients must be 18 to 65 years of age inclusive, at the time of signing the informed
             consent.

          2. Stable mandibular ramus injury or defect due to trauma, disease, or congenital
             defects.

          3. Medical history must be verified by either a personal physician or medical
             practitioner as appropriate.

          4. Patient determined by the Investigator to be a suitable candidate by medical
             evaluation, including medical history, physical examination, laboratory tests, and
             cardiac evaluation.

          5. A female patient is eligible to participate if she is not pregnant (see Appendix 6),
             not breastfeeding, and at least 1 of the following conditions applies:

               1. A woman of nonchildbearing potential (WONCBP) as defined in Appendix 6. OR

               2. A woman of childbearing potential (WOCBP) who agrees to follow the contraceptive
                  guidance in Appendix 6 for at least 1 month prior to surgery, during the
                  treatment period, and until 12 weeks after completion of the study.

          6. Patient must be available at the study center for all specified assessments throughout
             the study duration.

          7. Patients whose clinical laboratory test results are within the reference range for
             healthy individuals, or where outside the reference range is judged as not clinically
             relevant by the Investigator.

          8. All patients are required to give written informed consent as described in Appendix 2,
             which includes compliance with the requirements and restrictions listed in the
             informed consent form (ICF) and in this protocol, and in accordance with the
             Declaration of Helsinki, before enrollment. Patients must provide written informed
             consent and authorization for use and disclosure of protected health information.

          9. A healthy condyle which can be plated with titanium plates and screws.

         10. A mandibular continuity ramus defect which starts below the sigmoid notch and extends
             only as far as but not including the angle.

        Exclusion Criteria

          1. Uncontrolled alcohol, tobacco, or substance abuse within 6 months prior to
             implantation.

          2. Mandibular ramus defects with open wounds.

          3. Defects &gt; 15 cc in volume.

          4. Defects &gt; 6 cm in diameter.

          5. Systemic disease that would render the fat harvest and product implantation, along
             with associated anesthesia, unsafe to the patient.

          6. Patient has any underlying or current medical or psychiatric condition that, in the
             opinion of the Investigator, would impact patient safety or interfere with the
             integrity of the study data.

          7. Active uncontrolled infection or malignancy. Patients will be allowed to undergo
             rescreening once, after the infection is cleared, if they are willing to do so.

          8. Patients with signs and symptoms of infection between Screening and up to the surgical
             implantation.

          9. Radiation therapy &lt; 6 months prior to the surgical implantation.

         10. Need for soft tissue reconstruction (flap, skin graft, etc).

         11. Conditions that may impact the success of the surgical implantation or increase the
             risk of postoperative complications, including inherited coagulopathies like
             hemophilia, Von Willebrand's disease, protein C and S deficiency, thrombocythemias,
             thallassemias, sickle cell disease, etc.

         12. Conditions that may impact functional outcomes, including uncontrolled diabetes,
             osteoporosis, rare disorders of bone healing like osteopetrosis, or any other
             metabolic bone disease.

         13. Increased alkaline phosphatase (to exclude Paget's disease), increased serum calcium
             (to exclude hyperparathyroidism), or Vitamin D deficiency, at Screening, confirmed by
             a repeat test.

         14. Oral bisphosphonate &lt; 12 weeks, intravenous bisphosphonate &lt; 12 months prior to
             Screening or use of systemic steroids or anabolic agents (e.g. teriparatide) for
             osteoporosis treatment.

         15. Patients with inadequate donor sites for lipoaspirate of adipose tissue.

         16. Mixed connective tissue diseases and collagen diseases which can result in poor wound
             healing after surgery.

         17. Patients considered unsuitable per the consulted surgeon.

         18. Patient has any of the following conditions as identified by medical history:

               1. Human immunodeficiency virus (active or seropositive).

               2. Active tuberculosis.

               3. Active hepatitis B infection.

               4. Hepatitis C.

               5. Viral encephalitis.

               6. Toxoplasmosis. In case of doubt regarding mentioned conditions based on the
                  physical examination or other signs or symptoms present at Screening, the patient
                  will be asked to consent to additional testing to rule out such conditions or the
                  patient must be excluded from the study.

         19. Donation of blood and blood products is not permitted from Screening and for at least
             3 months after the surgical implantation.

         20. Patient participated in another clinical study of an investigational drug within 30
             days or 5 half-lives of the investigational drug (whichever is longer) prior to the
             surgical implantation or is currently participating in another clinical study of an
             investigational drug or intending to participate in another clinical study of an
             investigational drug before completion of all scheduled evaluations in this clinical
             study.

         21. Patients who, in the opinion of the Investigator, are not likely to complete the study
             for whatever reason.

         22. The Investigator or any sub-investigator, research assistant, surgeon, study
             coordinator, or other staff directly involved in the conduct of the clinical study or
             any of their relatives.

         23. Hypersensitivity to any product of bovine origin.

         24. Hypersensitivity to gentamicin or other aminoglycosides.

         25. Post-menopausal women who have an abnormally low bone mineral density or have not
             tested for bone mineral density.

         26. Patients with discontinuity defects of the ramus.

         27. Patients with a history of malignant cancer.

         28. Hypersensitivity or allergy to epinephrine or other drugs commonly used during
             surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian R Gastman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian R Gastman, MD</last_name>
    <phone>216-444-9419</phone>
    <email>gastmab@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brian R Gastman, MD</last_name>
      <phone>216-444-9419</phone>
      <email>gastmab@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.epibone.com</url>
    <description>EpiBone, Inc.</description>
  </link>
  <reference>
    <citation>Bhumiratana S, Bernhard JC, Alfi DM, Yeager K, Eton RE, Bova J, Shah F, Gimble JM, Lopez MJ, Eisig SB, Vunjak-Novakovic G. Tissue-engineered autologous grafts for facial bone reconstruction. Sci Transl Med. 2016 Jun 15;8(343):343ra83. doi: 10.1126/scitranslmed.aad5904.</citation>
    <PMID>27306665</PMID>
  </reference>
  <reference>
    <citation>Bhumiratana S, Vunjak-Novakovic G. Concise review: personalized human bone grafts for reconstructing head and face. Stem Cells Transl Med. 2012 Jan;1(1):64-9. doi: 10.5966/sctm.2011-0020. Epub 2011 Dec 7. Review.</citation>
    <PMID>23197642</PMID>
  </reference>
  <reference>
    <citation>Grayson WL, Marolt D, Bhumiratana S, Fr√∂hlich M, Guo XE, Vunjak-Novakovic G. Optimizing the medium perfusion rate in bone tissue engineering bioreactors. Biotechnol Bioeng. 2011 May;108(5):1159-70. doi: 10.1002/bit.23024. Epub 2010 Dec 22.</citation>
    <PMID>21449028</PMID>
  </reference>
  <reference>
    <citation>Grayson WL, Bhumiratana S, Cannizzaro C, Vunjak-Novakovic G. Bioreactor cultivation of functional bone grafts. Methods Mol Biol. 2011;698:231-41. doi: 10.1007/978-1-60761-999-4_18.</citation>
    <PMID>21431523</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tissue engineering, tissue engineered product, mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mandibular Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

